287 related articles for article (PubMed ID: 16405921)
21. Gastric acid secretion: activation and inhibition.
Sachs G; Prinz C; Loo D; Bamberg K; Besancon M; Shin JM
Yale J Biol Med; 1994; 67(3-4):81-95. PubMed ID: 7502535
[TBL] [Abstract][Full Text] [Related]
22. Turnover of the gastric H+,K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion.
Gedda K; Scott D; Besancon M; Lorentzon P; Sachs G
Gastroenterology; 1995 Oct; 109(4):1134-41. PubMed ID: 7557078
[TBL] [Abstract][Full Text] [Related]
23. Acid secretion and the H,K ATPase of stomach.
Prinz C; Kajimura M; Scott D; Helander H; Shin J; Besancon M; Bamberg K; Hersey S; Sachs G
Yale J Biol Med; 1992; 65(6):577-96. PubMed ID: 1341065
[TBL] [Abstract][Full Text] [Related]
24. Application of a combined effect compartment and binding model for gastric acid inhibition of AR-HO47108: a potassium competitive acid blocker, and its active metabolite AR-HO47116 in the dog.
Abelö A; Andersson M; Holmberg AA; Karlsson MO
Eur J Pharm Sci; 2006 Oct; 29(2):91-101. PubMed ID: 16831536
[TBL] [Abstract][Full Text] [Related]
25. [Proton pump inhibitors: Tenatoprazole (TU-199)].
Nakamura T
Nihon Rinsho; 2002 Feb; 60 Suppl 2():650-4. PubMed ID: 11979864
[No Abstract] [Full Text] [Related]
26. Revealing the Mechanistic Pathway of Acid Activation of Proton Pump Inhibitors To Inhibit the Gastric Proton Pump: A DFT Study.
Jana K; Bandyopadhyay T; Ganguly B
J Phys Chem B; 2016 Dec; 120(51):13031-13038. PubMed ID: 27992223
[TBL] [Abstract][Full Text] [Related]
27. Inhibitor and ion binding sites on the gastric H,K-ATPase.
Munson K; Garcia R; Sachs G
Biochemistry; 2005 Apr; 44(14):5267-84. PubMed ID: 15807521
[TBL] [Abstract][Full Text] [Related]
28. Review article: the clinical pharmacology of proton pump inhibitors.
Sachs G; Shin JM; Howden CW
Aliment Pharmacol Ther; 2006 Jun; 23 Suppl 2():2-8. PubMed ID: 16700898
[TBL] [Abstract][Full Text] [Related]
29. Soraprazan: setting new standards in inhibition of gastric acid secretion.
Simon WA; Herrmann M; Klein T; Shin JM; Huber R; Senn-Bilfinger J; Postius S
J Pharmacol Exp Ther; 2007 Jun; 321(3):866-74. PubMed ID: 17369284
[TBL] [Abstract][Full Text] [Related]
30. The gastric H,K-ATPase blocker lansoprazole is an inhibitor of chloride channels.
Schmarda A; Dinkhauser P; Gschwentner M; Ritter M; Fürst J; Scandella E; Wöll E; Laich A; Rossmann H; Seidler U; Lang F; Paulmichl M
Br J Pharmacol; 2000 Feb; 129(3):598-604. PubMed ID: 10711360
[TBL] [Abstract][Full Text] [Related]
31. A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog.
Abelö A; Eriksson UG; Karlsson MO; Larsson H; Gabrielsson J
J Pharmacol Exp Ther; 2000 Nov; 295(2):662-9. PubMed ID: 11046103
[TBL] [Abstract][Full Text] [Related]
32. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers.
Galmiche JP; Bruley Des Varannes S; Ducrotté P; Sacher-Huvelin S; Vavasseur F; Taccoen A; Fiorentini P; Homerin M
Aliment Pharmacol Ther; 2004 Mar; 19(6):655-62. PubMed ID: 15023167
[TBL] [Abstract][Full Text] [Related]
33. The gastric H,K ATPase as a drug target: past, present, and future.
Sachs G; Shin JM; Vagin O; Lambrecht N; Yakubov I; Munson K
J Clin Gastroenterol; 2007 Jul; 41 Suppl 2(Suppl 2):S226-42. PubMed ID: 17575528
[TBL] [Abstract][Full Text] [Related]
34. Identification of the site of inhibition by omeprazole of a alpha-beta fusion protein of the H,K-ATPase using site-directed mutagenesis.
Lambrecht N; Corbett Z; Bayle D; Karlish SJ; Sachs G
J Biol Chem; 1998 May; 273(22):13719-28. PubMed ID: 9593713
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of H+/K+ ATPase in the gastroprotective effect of Baccharis illinita DC.
Freitas CS; Baggio CH; Finau J; Anginoni M; Pizzolatti MG; Santos AR; Marques MC
J Pharm Pharmacol; 2008 Aug; 60(8):1105-10. PubMed ID: 18644203
[TBL] [Abstract][Full Text] [Related]
36. AHR-9294: a novel inhibitor of H,K-ATPase antagonizes gastric HCl secretion in vivo.
Reenstra WW; Pinkus LM; Bailey J; Smith WL; Droppleman D; Sancilio LF; Forte JG
J Pharmacol Exp Ther; 1992 May; 261(2):737-45. PubMed ID: 1315865
[TBL] [Abstract][Full Text] [Related]
37. Omeprazole: mode of action and effect on acid secretion in animals.
Wallmark B
Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():101-6. PubMed ID: 2657278
[TBL] [Abstract][Full Text] [Related]
38. Membrane topology and omeprazole labeling of the gastric H+,K(+)-adenosinetriphosphatase.
Besancon M; Shin JM; Mercier F; Munson K; Miller M; Hersey S; Sachs G
Biochemistry; 1993 Mar; 32(9):2345-55. PubMed ID: 8382947
[TBL] [Abstract][Full Text] [Related]
39. Novel imidazo[1,2-a]pyrazine derivatives as potent reversible inhibitors of the gastric H+/K+-ATPase.
Zimmermann PJ; Brehm C; Buhr W; Palmer AM; Volz J; Simon WA
Bioorg Med Chem; 2008 Jan; 16(1):536-41. PubMed ID: 17964794
[TBL] [Abstract][Full Text] [Related]
40. Nicotinamide derivatives as a new class of gastric H+/K(+)-ATPase inhibitors. 1. Synthesis and structure-activity relationships of N-substituted 2-(benzhydryl- and benzylsulfinyl)nicotinamides.
Terauchi H; Tanitame A; Tada K; Nakamura K; Seto Y; Nishikawa Y
J Med Chem; 1997 Jan; 40(3):313-21. PubMed ID: 9022797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
